NASDAQ: CERSCerus Corp Stock
$1.32-0.05 (-3.65%)
Updated Jun 13, 2025
CERS Price
$1.32
Fair Value Price
N/A
Market Cap
$252.33M
52 Week Low
$1.12
52 Week High
$2.54
P/E
-13.2x
P/B
4.55x
P/S
1.26x
PEG
N/A
Dividend Yield
N/A
Revenue
$206.78M
Earnings
-$18.95M
Gross Margin
60.6%
Operating Margin
-4.83%
Profit Margin
-9.2%
Debt to Equity
2.71
Operating Cash Flow
$9M
Beta
1.67
Next Earnings
Jul 30, 2025
Ex-Dividend
N/A
Next Dividend
N/A
CERS Overview
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CERS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
CERS
Ranked#45 of 108
Ranked#45 of 108
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $29.39 | A | |
| $12.10 | A | |
| $20.07 | A |
Be the first to know about important CERS news, forecast changes, insider trades & much more!
CERS News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CERS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CERS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
CERS is poor value based on its book value relative to its share price (4.55x), compared to the US Medical Devices industry average (3.99x)
P/B vs Industry Valuation
CERS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more CERS due diligence checks available for Premium users.
Valuation
CERS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-13.2x
Industry
35.6x
Market
31.36x
CERS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.55x
Industry
3.99x
CERS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CERS's financial health
Profit margin
Revenue
$48.9M
Net Income
-$7.7M
Profit Margin
-15.8%
CERS's Earnings (EBIT) of -$9.99M... subscribe to Premium to read more.
Interest Coverage Financials
CERS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$206.8M
Liabilities
$150.5M
Debt to equity
2.71
CERS's short-term assets ($161.52M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CERS's short-term assets ($161.52M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CERS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
CERS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$844.0k
Investing
-$1.2M
Financing
$1.1M
CERS's operating cash flow ($8.56M)... subscribe to Premium to read more.
Debt Coverage Financials
CERS vs Medical Device Stocks
Cerus Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.